PMPaul N. Mainwaring

Paul N. Mainwaring

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paul N. Mainwaring has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Abstract 5425: Novel molecular subtypes identified in prostate cancer: Results from the SPARTAN study

    by Clemente Aguilar, Michael Gormley, Shibu Thomas, Paul N. Mainwaring, David Olmos, Fred Saad, Simon Chowdhury, Elai Davicioni, Yang Liu, Deborah S. Ricci, et al.

    Background: Results from SPARTAN, a phase III placebo (PBO)-controlled study in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC), show that apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) significantly improves metastasis-free survival (MFS) compared with PBO + ADT. This analysis investigated the effects of APA in biologically distinct molecular subclasses of prostate cancer defined by gene expression profiles. Methods: Gene expression profiles (DECIPHER® prostate test, San Diego, CA) were generated from 233 archival primary prostate tumors; data were summarized based on 160 predefined gene signatures indicative of clinical prognosis and prostate cancer-related biology. Unsupervised consensus clustering identified sets of co-regulated expression signatures, and associations between signature expression, treatment, and signature-treatment interaction with MFS were evaluated using Kaplan-Meier analysis and Cox proportional hazards models. Results: Four co-regulated expression signature classes, each with distinct biological pathway functions, were identified. Class C1 included prognosis-related (risk) signatures; C2 included steroid homeostasis-related signatures; C3 included hormonal therapy nonresponsive basal and neuroendocrine-like signatures; C4 included immune and stromal signatures. Increased C1 expression was associated with shorter MFS in the PBO group (HR [95% CI], 2.18 [1.11-4.28], p = 0.02), while it was associated with longer MFS in the APA group (interaction HR [95% CI], APA vs PBO, 0.36 [0.14-0.95], p = 0.04). Similarly, increased C2 expression was associated with shorter MFS in the PBO group (HR [95% CI], 1.42 [1.02-1.98], p = 0.04), while it was associated with longer MFS in the APA group (interaction HR [95% CI], APA vs PBO, 0.57 [0.35-0.93], p = 0.02). Although there is no significant interaction effect between signature and treatment in C3, pts with low expression of C3 (adeno-like) showed longer MFS on APA vs PBO (HR [95% CI], 0.23 [0.13-0.40], p < 0.0001) compared with high-C3-expressing neuroendocrine-like tumors. Increased C4 expression was associated with decreased risk of metastasis in the APA group (HR [95% CI], 0.55 [0.35-0.86], p = 0.008) compared with PBO (interaction HR [95% CI], APA vs PBO, 0.53 [0.28-0.98], p = 0.04). Conclusion: Expression signatures were clustered into 4 correlated unique biological subclasses. Clinical benefit of APA + ADT was observed in pts with expression profiles with high risk (C1), C2, C3, or C4 compared with PBO + ADT. Citation Format: Clemente Aguilar, Michael Gormley, Shibu Thomas, Paul N. Mainwaring, David Olmos, Fred Saad, Simon Chowdhury, Elai Davicioni, Yang Liu, Deborah S. Ricci, Angela Lopez-Gitlitz, Margaret K. Yu, Matthew R. Smith, Eric J. Small, Felix Feng. Novel molecular subtypes identified in prostate cancer: Results from the SPARTAN study [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5425.

  • Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTAN.

    by Julie Nicole Graff, Matthew Raymond Smith, Fred Saad, Boris A. Hadaschik, Hiroji Uemura, Ji Youl Lee, Paul N. Mainwaring, David Olmos, Stephane Oudard, Anil Londhe, et al.

    5024 Background: SPARTAN, a randomized phase 3 placebo (PBO)-controlled study in pts with high-risk nmCRPC and PSA doubling time ≤ 10 mo, showed that, compared with PBO, addition of APA to ongoing ADT treatment (tx) prolonged metastasis-free survival (MFS) by > 2 y, reduced the risk of symptomatic progression by 55%, and increased second progression-free survival (PFS2), which is the time from randomization to disease progression on first subsequent anticancer tx, or death. The impact of APA in terms of benefit and safety profile was evaluated in pts aged < 65, 65-74, and ≥ 75 y. Methods: Pts with nmCRPC were randomized 2:1 to APA (240 mg QD) or PBO; ADT was continuous. APA effect was analyzed by Cox models and Kaplan-Meier methods across age subgroups. Results: Baseline characteristics among age groups were similar, although ECOG PS 1 vs 0 increased with age. MFS benefit with APA was highly significant for all age subgroups (Table). In pts ≥ 75 y, MFS risk with APA vs PBO was reduced by 59%; MFS risk was reduced by 86% and 76% for pts < 65 and 65-74 y, respectively. Risk of PFS2 with APA vs PBO was reduced across all age subgroups. PFS2 in pts < 65, 65-74, and ≥ 75 y: HR, 0.09 (p < 0.0001); HR, 0.56 (p = 0.0343); HR, 0.59 (p = 0.0092), respectively. Risk of symptomatic progression was lessened with APA vs PBO for all age subgroups (Table). There was a similar increase in incidence of tx-emergent adverse events (TEAE) with age in both tx arms that remained higher with APA. Incidence of grade 3/4 TEAE (≥ 75 vs < 65 y): APA, 50% vs 37%; PBO, 37% vs 28%. Conclusions: Pts in all age subgroups with high-risk nmCRPC had significant improvement in MFS with APA + ongoing ADT. The safety profile of APA was similar across age subgroups. Clinical trial information: NCT01946204. [Table: see text]


  • Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).

    by Toni K. Choueiri, Thomas Powles, Bernard J. Escudier, Nizar M. Tannir, Paul Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, et al.

    4506 Background: Cabo is an inhibitor of tyrosine kinases including MET, VEGF receptors, and AXL, which are oncogenic drivers in RCC. In the METEOR trial (NCT01865747), Cabo showed a statistically significant improvement in progression-free survival (PFS, the primary endpoint) compared with Eve in pts with previously treated RCC (median of 7.4 vs 3.8 mo; HR=0.58, 95% CI 0.45–0.75; P <0.001) and improved the objective response rate (Choueiri NEJM 2015). The safety profile of Cabo was acceptable and similar to other VEGFR TKIs in this population. Interim analysis of the secondary endpoint of OS with a minimum follow-up of 6 mo revealed a favorable trend for Cabo vs Eve (HR=0.67, 95% CI 0.51–0.89; P=0.005). Here we present the final OS results, arising from a second interim analysis. Methods: Pts with measurable clear cell RCC, KPS ≥70, and ≥1 prior VEGFR TKI were randomized 1:1 to Cabo (60 mg qd) or Eve (10 mg qd) stratified by MSKCC risk group and number of prior VEGFR TKIs (1 or ≥2). The study was designed to detect a HR for OS of 0.75 (80% power, 2-sided α=0.04). Results: From Aug 2013–Nov 2014, 658 pts were randomized. As of 31 Dec 2015, with a minimum follow-up of 13 mo, 320 deaths were recorded (140 for Cabo and 180 for Eve). 74 (22%) pts remained on therapy in the Cabo arm vs 25 (8%) pts in the Eve arm. The secondary endpoint of improved OS for Cabo-treated pts was met. The median OS was 21.4 mo for Cabo vs 16.5 mo for Eve, with a 33% reduction in the rate of death (HR 0.67, 95% CI 0.53 to 0.83, P=0.0003). Landmark estimates of survival at 18 mo were 58% in the Cabo arm vs 47% of the Eve arm. OS benefit with Cabo was consistently observed across all prespecified subgroups including MSKCC risk group, number and type of prior VEGFR TKIs, prior anti-PD-1/PD-L1 treatment, location and extent of tumor metastases, and tumor MET expression level. SAEs were consistent with the safety profile previously reported. Conclusions: Cabo is the only agent to demonstrate a significant benefit in OS, PFS, and ORR in a Phase 3 trial in previously treated pts with advanced RCC. Cabo is an important new treatment option for these patients. Clinical trial information: NCT01865747.


  • 4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial

    by T. Choueiri, B. Escudier, T. Powles, P. Mainwaring, B. Rini, F. Donskov, H. Hammers, T. Hutson, B. Roth, K. Peltola, et al.

  • Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.

    by Mario A. Eisenberger, Anne-Claire Hardy-Bessard, Loic Mourey, Paul N. Mainwaring, Daniel Ford, Jeremy David Shapiro, Joan Carles, Siobhan Ng, Thierry Gil, Boris Alekseev, et al.

    TPS4692^ Background: The phase III TROPIC study (NCT00417079) reported a significant improvement in overall survival (OS) for cabazitaxel (Cbz) + prednisone (P;CbzP) (25 mg/m2 IV Q3W/10 mg PO QD) vs mitoxantrone (M) + P (MP) (median OS 15.1 vs 12.7 mos; HR 0.70; P < 0.0001) in pts with mCRPC (also known as hormone-refractory prostate cancer) previously treated with a D-containing regimen. CbzP is approved by the FDA, EMA and other health authorities for the treatment of pts with mCRPC that has progressed after a D-containing regimen. Cbz toxicity is consistent with other taxanes; compared with M, more hematologic toxicities are reported (primarily Grade 3–4 neutropenia). Phase I/II studies identified 20 and 25 mg/m2 as recommended doses; 25 mg/m2 was selected for the phase III TROPIC study. As pooled data show Grade 3–4 neutropenia incidence is lower with Cbz < 25 mg/m2 (61%) vs ≥ 25 mg/m2 (74%), it is of interest to assess if reducing the Cbz approved dose in mCRPC lessens hematologic toxicity and is non-inferior in terms of efficacy. Methods: PROSELICA (NCT01308580) is a randomized, open-label, multinational, phase III study comparing 20 mg/m2 and 25 mg/m2 Cbz for efficacy and tolerability. Pts with a life expectancy > 6 mos, ECOG PS ≤ 2, histologically/cytologically confirmed metastatic prostate adenocarcinoma resistant to hormone therapy and previously treated with a D-containing regimen are eligible. Pts are randomized 1:1 to receive Cbz 20 mg/m² or 25 mg/m² IV Q3W + P 10 mg PO QD, treated until disease progression, unacceptable toxicity or withdrawal of consent (max 10 cycles), and stratified according to ECOG PS, measurable disease (yes/no) and region. The primary endpoint is OS (non-inferiority design). Secondary endpoints include safety, progression-free survival (PCWG2 criteria), PSA and pain progression and response, tumor response in pts with measurable disease and health-related quality of life. Cbz PK and pharmacogenomics will be assessed in pt subgroups. Planned enrollment is 1,200 pts. Study start was in May 2011; as of Jan 2012, 270 pts had been enrolled. The first DMC meeting recommended continuing the study without change.


  • Open Access

    Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC

    by Roberto Pili, Mark A. Rosenthal, Paul N. Mainwaring, Guy Van Hazel, Sandy Srinivas, Robert Dreicer, Sanjay Goel, Joseph Leach, Shirley Wong, Peter Clingan

    Purpose: This randomized phase II study evaluated ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) in combination with docetaxel in castration-refractory metastatic prostate cancer (CRMPC). Experimental Design: Seventy-four patients with histopathologically confirmed CRMPC previously untreated with chemotherapy were randomized to receive either ≤10 cycles of docetaxel 75 mg/m2 alone (D; n = 39) or docetaxel plus ASA404 1,200 mg/m2 (A-D; n = 35). Study endpoints included prostate-specific antigen response, tumor response, median time to tumor progression, median survival, and toxicity. Results: The overall pattern of adverse events was similar in the two groups; however, there was a higher incidence of cardiac adverse events and neutropenia in the A-D group. Coadministration of ASA404 with docetaxel did not affect total systemic exposure of either drug. A higher prostate-specific antigen response rate was reported with A-D versus D (59.4% versus 36.8%), together with a larger median percentage reduction in prostate-specific antigen (84.0% versus 61.9%) and a shorter median time to prostate-specific antigen nadir (105 versus 119 d). Tumor response rate was 23.1% with A-D and 9.1% with D. Time to tumor progression and median survival were similar in the groups (time to tumor progression, 8.7 mo for A-D and 8.4 mo for D; survival, 17.0 mo for A-D and 17.2 mo for D). Hazard ratios for time to tumor progression and survival were 0.81 and 0.80, respectively, favoring A-D; 2-year survival was 33.3% with A-D and 22.8% with D. Conclusion: The study met some endpoints (prostate-specific antigen response, tumor response) but not others (i.e., time to tumor progression). The results indicate that the combination of ASA404 with docetaxel has acceptable toxicity, lacks adverse pharmacokinetic interaction, and, overall, has activity in CRMPC. Clin Cancer Res; 16(10); 2906–14. ©2010 AACR.


  • Phase 1a safety and pharmacokinetic study of oral NV-196 in patients with solid tumours

    by P. N. Mainwaring, L. West, A. J. Husband

    14615 Background: NV-196 antagonizes the anti-apoptotic factors that block the tumour necrosis factor-related apoptosis- inducing ligand (TRAIL) death receptors. NV-196 is broadly cytostatic and cytotoxic against most forms of human cancer cells in vitro, and is a potent chemo-sensitizer of most standard chemotoxic agents. Methods: Participants with a stable, solid malignancy, an estimated life-expectancy of at least 3 months, adequate renal, hepatic and haematological function and a Karnofsky PS ≥ 60% participated. Participants received a single oral dose of 100mg NV-196 on D1 with serial blood and urine samples collected for pharmacokinetic analysis for NV-196 and its metabolite NV-143 over the following 2 days. Repeated dosing began on day 3 with 100 mg NV-196 administered 8- hourly for 5 days until the morning of the 8th day when patients received their last dose of NV-196. Physical examination, AE reporting, vital signs and clinical laboratory testing was conducted to determine the safety and tolerability of NV-196. Free and total (unconjugated plus conjugated) NV-196 and NV-143 concentrations were determined using liquid chromatography tandem mass spectrometry, with validated and non-validated methods, respectively. Results: Eight female and 5 male subjects consented to participation: 2 prostate, 1 fallopian, 2 breast, 2 ovarian, 1 gastric, 2 colorectal, 1 bladder, 1 melanoma and 1 adrenal. Mean Tmax, Cmax, t1/2, λt and AUC0–24h values for conjugated NV-196 and conjugated NV-143 in the single and repeat dose phases were obtained and will be presented. Steady state concentrations of conjugated NV-196 and NV-143 were reached within three days of dosing in the repeat dose phase. NV-196 was excreted predominantly in a conjugated state. There were two unrelated Serious Adverse Events - 1 abdominal pain and 1 bowel obstruction which both required hospitalization. There was one case of Grade 4 toxicity for anemia. Conclusions: The three times daily dosing regime was successful in achieving elevated plasma concentrations of NV- 196 and NV-143 in their conjugated forms. Recovery of NV-196 and its metabolites in the urine was low a result which may reflect the incomplete absorption of NV-196 and/or suggests the contribution of excretion via the bile duct without significant toxicity.